PMID- 37298023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230612
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 12
IP  - 11
DP  - 2023 Jun 2
TI  - Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line 
      Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
LID - 10.3390/jcm12113828 [doi]
LID - 3828
AB  - (1) Background: At present, the efficacy and safety of thoracic radiotherapy 
      (TRT) after chemo-immunotherapy (CT-IT) in patients with extensive-stage 
      small-cell lung cancer (ES-SCLC) still remain unclear. The purpose of this study 
      was to evaluate the role of TRT after CT-IT in patients with ES-SCLC. (2) 
      Methods: From January 2020 to October 2021, patients with ES-SCLC treated with 
      first-line anti-PD-L1 antibody plus platinum-etoposide chemotherapy were enrolled 
      retrospectively. The survival data and adverse events data of patients treated 
      with or without TRT after CT-IT were collected for analysis. (3) Results: A total 
      of 118 patients with ES-SCLC treated with first-line CT-IT were retrospectively 
      enrolled, with 45 patients with TRT and 73 patients without TRT after CT-IT. The 
      median PFS and OS in the CT-IT + TRT group and CT-IT only group were 8.0 months 
      versus 5.9 months (HR = 0.64, p = 0.025) and 22.7 months versus 14.7 months (HR = 
      0.52, p = 0.015), respectively. The median PFS and OS in all 118 patients treated 
      with first-line CT-IT were 7.2 and 19.8 months with an ORR of 72.0%. In 
      multivariate analyses, liver metastasis and response to CT-IT were shown to be 
      independent prognostic factors of PFS (p < 0.05), while liver metastasis and bone 
      metastasis were independent predictive factors of OS (p < 0.05). Although TRT was 
      significantly associated with better PFS and OS in univariate analysis, the 
      association of TRT and OS failed to reach statistical significance (HR = 0.564, p 
      = 0.052) in multivariate analysis. There was no significant difference in adverse 
      events (AEs) between two treatment groups (p = 0.58). (4) Conclusions: ES-SCLC 
      patients treated with TRT after first-line CT-IT had prolonged PFS and OS with an 
      acceptable safety profile. Further prospective randomized studies are necessary 
      to explore the efficacy and safety of this treatment modality for ES-SCLC in 
      future.
FAU - Xie, Zhaoliang
AU  - Xie Z
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Science, Jinan 
      250117, China.
FAU - Liu, Jingru
AU  - Liu J
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong University Cancer Center, Jinan 250117, China.
FAU - Wu, Min
AU  - Wu M
AD  - Suzhou Cancer Center Core Laboratory, The Affiliated Suzhou Hospital of Nanjing 
      Medical University, Suzhou 215000, China.
FAU - Wang, Xiaohan
AU  - Wang X
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Science, Jinan 
      250117, China.
FAU - Lu, Yuhan
AU  - Lu Y
AD  - Department of Emergency Medicine, The First People's Hospital of Neijiang, 
      Neijiang 641099, China.
FAU - Han, Chunyan
AU  - Han C
AD  - Department of Radiotherapy, The Third Affiliated Hospital of Shandong First 
      Medical University, Jinan 250031, China.
FAU - Cong, Lei
AU  - Cong L
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First 
      Medical University, Jinan 250117, China.
FAU - Li, Jisheng
AU  - Li J
AUID- ORCID: 0000-0002-4186-6228
AD  - Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan 
      250012, China.
FAU - Meng, Xue
AU  - Meng X
AD  - Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Science, Jinan 
      250117, China.
LA  - eng
GR  - 2019KJL001/Science and Technology Support Plan for Youth Innovation Teams of 
      Universities in Shandong Province/
GR  - flzh202106/Bethune . Translational Medicine Research Foundation for Tumor 
      Radiotherapy/
GR  - 81972864 and 82172720/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20230602
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10253710
OTO - NOTNLM
OT  - adverse event
OT  - chemo-immunotherapy (CT-IT)
OT  - extensive-stage small-cell lung cancer (ES-SCLC)
OT  - survival
OT  - thoracic radiotherapy (TRT)
COIS- The authors declared that there was no conflict of interest regarding the 
      publication of this paper.
EDAT- 2023/06/10 15:13
MHDA- 2023/06/10 15:14
PMCR- 2023/06/02
CRDT- 2023/06/10 01:10
PHST- 2023/02/08 00:00 [received]
PHST- 2023/05/04 00:00 [revised]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/06/10 15:14 [medline]
PHST- 2023/06/10 15:13 [pubmed]
PHST- 2023/06/10 01:10 [entrez]
PHST- 2023/06/02 00:00 [pmc-release]
AID - jcm12113828 [pii]
AID - jcm-12-03828 [pii]
AID - 10.3390/jcm12113828 [doi]
PST - epublish
SO  - J Clin Med. 2023 Jun 2;12(11):3828. doi: 10.3390/jcm12113828.